Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 1480-1487, March 1, 2007. doi: 10.1158/1078-0432.CCR-06-1716
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, D. T.
Right arrow Articles by Paradis, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, D. T.
Right arrow Articles by Paradis, H.

Imaging, Diagnosis, Prognosis

Tubedown Expression Correlates with the Differentiation Status and Aggressiveness of Neuroblastic Tumors

Darryl T. Martin1, Robert L. Gendron1, Jason A. Jarzembowski2, Arie Perry3, Margaret H. Collins4, Chitra Pushpanathan1, Ewa Miskiewicz1, Valerie P. Castle2 and Hélène Paradis1

Authors' Affiliations: 1 Department of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; 2 Department of Pathology, University of Michigan Hospitals and Clinics, Ann Arbor, Michigan; 3 Division of Neuropathology, Washington University School of Medicine, St. Louis, Missouri; and 4 Department of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Requests for reprints: Hélène Paradis, Department of Medicine, Memorial University of Newfoundland, 300 Prince Philip Drive, St. John's, Newfoundland, Canada A1B 3V6. Phone: 709-777-8556; Fax: 709-777-8619; E-mail: hparadis{at}mun.ca.

Purpose: The discovery and validation of new prognostic factors and further refinement of risk group stratification are needed to improve clinical interpretation of neuroblastoma. Our laboratory isolated and characterized a developmentally regulated gene named TUBEDOWN against which we have raised a monoclonal antibody (OE5). Tubedown becomes down-regulated postnatally yet remains strongly expressed in some neuroblastomas. The purpose of this study is to define the utility of Tubedown expression as a new measure of the differentiation status and aggressiveness of neuroblastic tumors.

Experimental Design: Tubedown protein expression was quantitatively assessed in neuroblastic tumors (neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) and normal adrenal tissues using Western blot and OE5 immunohistochemistry. Regulation of Tubedown expression during retinoic acid–induced neuronal differentiation in neuroblastoma cell lines was assessed by Western blotting.

Results: High levels of Tubedown expression are observed in tumors with significant neuroblastic component, unfavorable histopathology, advanced stage, high-risk group, and poor outcome. In contrast, more differentiated subsets of neuroblastic tumors, ganglioneuroblastomas with favorable histopathology and ganglioneuromas, express low levels of Tubedown. In vitro, marked retinoic acid–induced neuronal differentiation responses of neuroblastoma cells are associated with a significant decrease in Tubedown expression, whereas limited neuronal differentiation responses to retinoic acid were associated with little or no decrease in Tubedown expression.

Conclusions: Our results indicate that the levels of Tubedown expression are linked to the differentiation status and aggressiveness of neuroblastic tumors and represent an independent prognostic factor for neuroblastoma. Tubedown expression may be useful to more accurately define different neuroblastic tumor subsets and ultimately provide more adequate assessment and treatment for neuroblastoma patients.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
H. Paradis, T. Islam, S. Tucker, L. Tao, S. Koubi, and R. L. Gendron
Tubedown associates with cortactin and controls permeability of retinal endothelial cells to albumin
J. Cell Sci., June 15, 2008; 121(12): 1965 - 1972.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.